Opioids: Intellipharmaceutics' Pursuit Of IV-Only Deterrence Claim May Backfire

US FDA advisory committee may not be comfortable with intravenous abuse-deterrence labeling for Rexista (oxycodone extended-release) when the sponsor has not assessed the impact on other routes of abuse purportedly targeted by the formulation.